Answers are grounded in this paper and cite their sources.
Observational analysis demonstrates enhanced PEP efficacy against SHIV in macaques, suggesting pivotal role in HIV prevention.
LP-98 is a lipopeptide HIV fusion inhibitor showing strong treatment and pre-exposure prophylaxis efficacies in non-human primates. In this study, we further characterized its pharmacokinetics, long-lasting antiviral activity, and post-exposure prophylaxis (PEP) efficacy using 62 macaques. In cynomolgus macaques, LP-98 achieved high concentrations (Cmax) with a half-life (T1/2) of ∼31 h, and sustained an effective therapeutic concentration for two weeks post-injection. In chronically SHIVSF162P3-infected rhesus macaques (RMs), weekly or biweekly LP-98 monotherapy efficiently suppressed virus replication. In the PEP study, early LP-98 administration (weekly for 4 weeks) provided robust protection against SHIVSF162P3 infection through intrarectal and intravenous challenges. No viral DNA or replication-competent virus was detected in tissues from protected RMs, even after CD8+ T cell depletion. Transcriptomic analyses revealed the potential immunomodulatory effects of LP-98 treatment. Collectively, our results demonstrate the importance of LP-98 for HIV prevention and treatment and facilitate its current clinical studies.
No takes yet. Share an insight, caveat, or question.
Xue et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: